Sources: MHRA/EMC Wegovy SmPC, NICE TA875 (Semaglutide for managing overweight and obesity), NHS medicines information
One 2024 study in Cell Metabolism showed that a single low dose of GLP-1 reduces inflammation, independent of weight loss
While the study found that semaglutide specifically reduced the risk of atrial arrhythmias and atrial fibrillation (AF), other studies have reported conflicting results regarding the arrhythmia risk associated with GLP-1 RAs ( GLP-1RAs have been shown to significantly reduce postprandial levels of triglycerides, apolipoprotein (Apo) B48 and ApoC-III, independently of gastric emptying
d 9 -TMAO, m/z 85.1 66.3 and 85.1 68.3
People who significantly decrease their weight - whether through GLP-1s, behavioral programs or bariatric surgery - often lose muscle mass at the same time
Marketing it for human ingestion is unlawful